Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Summary

This study will evaluate the safety and tolerability of bapineuzumab when administered by subcutaneous injection. The study is open only to subjects who participated in the preceding double-blind study (3133L1-2203 US). Subjects will receive weekly injections of bapineuzumab for 3 years (156 doses). One dosage level will be included: 5 mg/week. All subjects will receive active treatment (bapineuzumab) and no subjects will receive placebo.

Timeline

Start

2009-06

Primary completion

2012-09

Completion

2012-09

Outcome

Outcome not reported

Stopped: “The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.”

Drugs

Indications